{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:10:45Z","timestamp":1760735445477,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.114045","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T12:10:59Z","timestamp":1712664659000},"page":"114045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical trials of T-cell re-directing therapy in plasma cell precursor conditions"],"prefix":"10.1016","volume":"203","author":[{"given":"Samer","family":"Al Hadidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114045_bib1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/OTT.S370880","article-title":"Targeting B cell maturation antigen in patients with multiple myeloma: current perspectives","volume":"16","author":"Shrivastava","year":"2023","journal-title":"Onco Targets Ther"},{"issue":"11","key":"10.1016\/j.ejca.2024.114045_bib2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2024.114045_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114045_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102272","article-title":"Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey","volume":"65","author":"Mohyuddin","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"15","key":"10.1016\/j.ejca.2024.114045_bib5","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/bloodadvances.2023009658","article-title":"Is aggressive treatment of smoldering myeloma the path to curing myeloma?","volume":"7","author":"Chakraborty","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2024.114045_bib6","article-title":"Quick consults in hematology: in support of active surveillance versus treatment of high-risk smoldering multiple myeloma outside of a clinical trial","author":"Gertz","year":"2023","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.ejca.2024.114045_bib7","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2024.114045_bib8","unstructured":"Package Insert - CARVYKTI. Accecced January 6th 2024 https:\/\/www.fda.gov\/media\/156560\/download."},{"issue":"Published online December 5","key":"10.1016\/j.ejca.2024.114045_bib9","article-title":"Three years maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow up","author":"Al Hadidi","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.ejca.2024.114045_bib10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924007019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924007019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:03Z","timestamp":1760733783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924007019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":10,"alternative-id":["S0959804924007019"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114045","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trials of T-cell re-directing therapy in plasma cell precursor conditions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114045"}}